Daniel Chueh, MD
Psychiatry · Orange, CANPI 1174589642
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 44.8% of the total. Reporting peaked in 2024 at $36,363 and has fallen 57.5% since, to $15,440 in 2025. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 574 payments — averaging $132.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$34K
- Teva Pharmaceuticals USA, Inc.$29K
- Boehringer Ingelheim$2K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$2K
- Alkermes, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- plus $6K from 25 others
Across 1,509 payments — averaging $11,811 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$4.9M
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2.9M
- AbbVie$2.3M
- Sage Therapeutics, LLC$1.6M
- Otsuka Pharmaceutical Development & Commercialization, Inc.$1.5M
- Hoffmann-la Roche Limited$873K
- plus $3.8M from 19 others
What the payments were for
- Consulting fees$8,82312%
- Speaking & faculty fees$45,03059%
- Travel & lodging$8,10111%
- Food & beverage$14,08919%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 80 | $34,071 |
| Teva Pharmaceuticals USA, Inc. | 85 | $28,695 |
| Boehringer Ingelheim | 19 | $2,484 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 18 | $1,759 |
| Alkermes, Inc. | 47 | $1,640 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 75 | $1,260 |
| Johnson & Johnson | 44 | $1,065 |
| AbbVie(2 entities) | 50 | $1,047 |
| Jazz Pharmaceuticals Inc. | 1 | $750 |
| Sunovion Pharmaceuticals Inc. | 42 | $597 |
| Vanda Pharmaceuticals Inc. | 27 | $474 |
| E.r. Squibb & Sons, L.L.C. | 16 | $441 |
| Neurocrine Biosciences, Inc. | 16 | $432 |
| Axsome Therapeutics, Inc. | 5 | $219 |
| Avanir Pharmaceuticals, Inc. | 10 | $185 |
| Lundbeck LLC | 8 | $184 |
| Indivior Inc. | 9 | $161 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $99 |
| Bioxcel Therapeutics, Inc. | 2 | $79 |
| Eisai Inc. | 2 | $71 |
| Novo Nordisk | 3 | $66 |
| Ironshore Pharmaceuticals Inc. | 2 | $54 |
| Lilly USA, LLC | 2 | $43 |
| Noven Therapeutics, LLC | 2 | $37 |
| Acadia Pharmaceuticals Inc | 2 | $37 |
| Vertical Pharmaceuticals, LLC | 1 | $21 |
| OWP Pharmaceuticals, Inc. | 1 | $21 |
| Sun Pharmaceutical Industries Inc. | 1 | $20 |
| CMP Pharma, Inc. | 1 | $17 |
| Almatica Pharma LLC | 1 | $17 |
| Tris Pharma Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$33,660
- UZEDY$24,131
- LYBALVI$1,460
- ARISTADA$901
- AUSTEDO$602
- ABILIFY ASIMTUFII$339
- ABILIFY MAINTENA$238
- ARISTADA INITIO$225
- INVEGA SUSTENNA$150
- INVEGA TRINZA$150
- SPRAVATO$144
- Auvelity$124
- COBENFY$121
How this compares
$76,061 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 44 | $148,822 |
| IngrezzaValbenazine Tosylate | 23 | $66,211 |
| Aripiprazole OdtAripiprazole | 45 | $61,911 |
| Olanzapine OdtOlanzapine | 205 | $45,321 |
| RexultiBrexpiprazole | 33 | $38,932 |
| Clozapine OdtClozapine | 85 | $38,561 |
| Risperidone OdtRisperidone | 81 | $27,728 |
| Risperdal ConstaRisperidone Microspheres | 20 | $24,464 |
| Aripiprazole | 169 | $22,013 |
| Clozapine | 192 | $17,933 |
| Paliperidone ErPaliperidone | 39 | $17,152 |
| Risperidone ErRisperidone Microspheres | 17 | $12,307 |
| Quetiapine Fumarate | 466 | $9,699 |
| Lurasidone Hcl | 37 | $9,326 |
| NuedextaDextromethorphan Hbr/Quinidine | 23 | $8,848 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $1,065 | $173,28764 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $432 | $66,21123 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $34,071 | $38,93233 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $185 | $8,84823 claims |
| Lilly USA, LLCOlanzapine | $43 | $7,910351 claims |
| Boehringer IngelheimTradjenta | $2,484 | $2,64012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Orange
- Gustavo AlvaOrange$5.8M
- Rimal BeraOrange$138K
- Steven PotkinOrange$108K
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.